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Congenital nephrotic syndrome of the Finnish type (NPHS1)
is associated with the rapid development of glomerular and
tubulointerstitial fibrosis. Here we measured morphologic
and molecular changes in the peritubular capillaries of the
kidney in patients with NPHS1. Immunohistochemical
analysis for the endothelial cell marker CD31 showed marked
narrowing and a moderate but significant reduction in
peritubular capillary density, especially in areas of increased
collagen I and a-smooth muscle actin content. No evidence
of endothelial-mesenchymal transformation was found.
There was increased expression (up to 43-fold) of hypoxia
inducible factor-1a suggesting tubulointerstitial hypoxia.
Double-labeling for CD31 and vimentin showed small foci of
peritubular capillary loss and tubular cell damage. While the
amount of intercellular adhesion molecule-1 was upregulated
in endothelial cells, other adhesion molecules were only
modestly expressed. Vascular endothelial growth factor
expression was reduced by up to half and decreased
endothelial progenitor cell marker CD34 expression indicated
lack of vascular repair. Our results suggest that hypoxia in the
tubulointerstitium caused by hypoperfusion of glomerular
and tubulointerstitial capillaries and rarefaction of the latter
may be important for the rapid progression of fibrosis in the
kidneys of patients with NPHS1.
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Congenital nephrotic syndrome of the Finnish type (NPHS1)
is a genetic disorder caused by mutations in the NPHS1 gene
encoding for nephrin, which is a podocyte-specific protein
located at the slit diaphragm of kidney glomerulus.1,2 In
NPHS1, heavy proteinuria and podocyte foot process
effacement are present at birth, and progressive glomerular
and tubulointerstitial fibrosis develop during infancy.3–6
Although the NPHS1 glomeruli show early mesangial
expansion and narrowing of the glomerular capillaries, the
structure of the glomerular endothelium is quite well
preserved in kidneys removed at infancy.6,7 Besides fibrosis,
inflammation around glomeruli and oxidative stress has been
the prominent findings in the tubulointerstitium of NPHS1
kidneys.5
Recent studies have suggested that tubulointerstitial
microvasculature has an important role in the progression
of renal diseases and chronic transplant nephropathy.8–12 The
injury and loss of peritubular capillaries (PTCs) result in
impairment of oxygen and nutrient delivery to the tubules
and interstitial cells, correlating with fibrosis and tubular
atrophy.13–16 Chronic hypoxia in the interstitium and tubuli
has been suggested as a final common pathway to end-stage
renal failure.17,18 Most of these data come from animal
models, and less information is available from human kidney
diseases.19–21
In this work, we were interested in the possible signs of
injury and loss of PTCs in NPHS1 kidneys removed at
infancy. These kidneys serve as a unique human model for
studies on the pathology of proteinuric kidney diseases. We
studied the relationship of PTC network and interstitial
fibrosis as well as endothelial inflammatory response,
thrombi formation, and angiogenesis in PTCs of NPHS1
kidneys.
RESULTS
The histopathology in the NPHS1 kidneys nephrectomized
in infancy was mostly normal with intact tubuli and
glomeruli showing only slightly expanded mesangium.
However, sclerotic glomeruli surrounded by inflammatory
cell infiltrates, tubular dilatation, interstitial fibrosis, and
obliterating arteries were observed with advancing age
(Figure 1).
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Rarefaction of PTCs
In areas with well-preserved histology, the peritubular space
and capillaries (PTC) were narrow (Figure 1), which was
clearly visualized using immunohistochemical staining for
the endothelial cell marker CD31 (Figures 1 and 2). The
density of PTCs was evaluated by calculating the area fraction
(%) of CD31-positive PTCs in NPHS1 kidneys. In the
NPHS1 kidneys with mild changes the CD31 expression was
slightly reduced (0.073%/tubulus) compared with control
group 1 kidneys (0.085%/tubulus; adult nephrectomized
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Figure 1 | Histological lesions and PTCs in NPHS1 kidneys. (a) A low-magnification image ( 50) of a NPHS1 kidney removed at the age
of 8 months shows glomeruli with variable degrees of mesangial expansion and sclerosis. Sclerotic glomeruli are surrounded by
inflammatory cells (arrowheads). The arterioles are typically narrowed (arrow) and the tubuli are well preserved, although some dilatation is
evident (periodic acid silver methenamin staining). (b) Higher magnification image ( 400) shows oedemic tubuli and narrowed peritubular
space and capillaries (arrows). (c and d) Focal increase of peritubular fibrosis occurs with time. (e) The NPHS1 kidneys with well preserved
histology show regular staining of the endothelial cell marker CD31 (brown) and little vimentin expression (blue). (f) Focal increase of
vimentin expression is, however, an early event and is associated with reduced staining for CD31. (g) Double staining for CD31 and vimentin
shows clearly narrowed arterioles (arrows). (h–j) The expression of vimentin in peritubular space and tubuli is associated with reduced
amount of CD31 staining, indicating a relationship with tubular damage and PTC rarefaction. NPHS1, congenital nephrotic syndrome of the
Finnish type; PTC, peritubular space and capillaries.
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kidneys) (Po0.05) and control group 2 kidneys (0.082%/
tubulus; biopsy samples from proteinuric pediatric kidneys)
(P-value not significant) (Figure 2a–c). The association of
PTC density with interstitial changes was studied by counting
the CD31-positive PTC cross-sections per tubulus in areas
without and with peritubular collagen I staining. In the
NPHS1 kidneys, the number of PTCs decreased from 0.982/
tubulus (no fibrosis) to 0.800/tubulus (Po0.05) (fibrosis)
(Figure 2d–f). The PTC number per tubulus in control group
2 was 0.892 (P-value NS). Similarly, the number of PTCs per
tubulus was 1.064 in areas with little expression of a-smooth
muscle actin (a-SMA) as compared with 0.749 in areas with
high a-SMA expression (Po0.01) (Figure 2g–i). Possible
transformation of PTC endothelial cells to mesencymal cell
was studied by double immunofluorescence staining for
CD31 and a-SMA. The analysis of 96 visual fields in NPHS1
kidneys, however, did not show costaining of these two
markers (Figure 3a and b).
Increased expression of vimentin in the peritubular space
was an early event in NPHS1 kidneys. Double staining for
CD31 and vimentin showed that in NPHS1 kidneys vimentin
stained strongly both in endothelial cells and outside PTCs,
whereas in control kidneys vimentin expression was modest
and restricted to the endothelial cells (Figure 3c and d).
Interestingly, vimentin expression was associated with small
foci of PTC loss and tubular damage (Figure 1h–j).
Double staining of the two endothelial cell markers CD31
and CD34 gave a very similar pattern. As CD34 is also a
marker for endothelial/hematopoietic progenitor cells, which
possibly play a role in the healing of microvasculature, we
searched especially capillaries and cells strongly positive for
CD34 but less positive for CD31. Analysis of NPHS1 kidneys
showed one cellular focus in every sixth visual field (25/151),
but these were mostly present among cell infiltrates (Figure
3e–h) speaking against a decisive role of CD34-positive cells
in the maintenance of PTCs.
Endothelial cell adhesion molecules and their ligands
Upregulation of endothelial adhesion molecules and selectins
is believed to be important in triggering inflammatory and
fibrotic processes in kidneys. The expression of adhesion
molecules and their ligands was studied by immunohisto-
chemistry and PCR microarray. Overall, the expression of
adhesion molecules in PTCs of NPHS1 kidneys was moderate
(Figure 4a–e and j). The staining intensity for intercellular
adhesion molecule-1 (ICAM-1) was 1.5 times (Po0.01)
higher in NPHS1 kidneys as compared with control group 1,
whereas its expression was equal to control group 2.
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Figure 2 | The number of PTCs was reduced in NPHS1 kidneys. (a and b) Immunohistochemical staining for endothelial cell marker CD31
was used to visualize the PTC structures in control and NPHS1 kidneys. (c) The reduction of CD31 expression per number of tubulus
was observed in NPHS1 samples. (The number of visual fields analyzed: 103 in control group 1, 39 in control group 2, and 42 NPHS1
samples). (d–i) The number of PTCs was decreased in NPHS1 samples with strong expression (þ) of collagen I (number of visual fields
analyzed; 92) and a-SMA (number of visual fields analyzed; 95) when compared with samples with mild expression of () of collagen I and
a-SMA. (Original magnification 200) *Po0.05, **Po0.01.
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P-selectin expression was 2.1 (P-value NS) higher in NPHS1
kidneys as compared with control group 1. Surprisingly, very
little expression of vascular cell adhesion molecule-1
(VCAM-1) and E-selectin (endothelial leukocyte adhesion
molecule-1) was detected. Also, the staining for CD29 (b1-
integrin) was faint in control group 1 and NPHS1 kidneys.
The mRNA levels of the adhesion molecules were also
moderate showing upregulation of fibronectin, selectin L,
and VCAM-1 (Figure 5a).
In the peritubular space, the number of inflammatory cells
expressing the ligands for the endothelial adhesion molecules
varied (Figure 4f–i and k). The expression levels of leukocyte
function antigen-1 were 2.1 (Po0.01) and 3.3 (P-value NS)
times higher in NPHS1 kidneys as compared with control
groups 1 and 2, respectively. The correlation was observed in the
expression of ICAM-1 and its ligand leukocyte function
antigen-1 in all six individual patient samples. The expression
levels of P-selectin glycoprotein ligand-1 were 4.7 (Po0.01) and
2.3 (P-value NS) times higher in NPHS1 kidneys as compared
with control groups 1 and 2, respectively. For very late antigen-4
the numbers were 3.2 (P-value NS) and 2.8 (P-value NS). In the
PCR microarray, the mRNA-levels of P-selectin glycoprotein
ligand were clearly upregulated (Figure 5a).
Markers for hypoxia, thrombosis, and angiogenesis
The progression of tubulointerstitial injury in various renal
diseases is associated with chronic hypoxia. In NPHS1
kidneys, the hypoxia-inducible factor-1a (HIF-1a) was
detected around tubuli as positive nuclear staining and the
protein expression was 2.6 (Po0.05) and 43 (Po0.01) times
more prevalent in NPHS1 kidneys as compared with control
groups 1 and 2, respectively (Figure 6a–d). HIF-1a was also
upregulated in NPHS1 cortex lysates in western blot analysis
(Figure 6i and j). The expression was approximately two
times higher in NPHS1 cortex than in samples of control
group 1. Vascular endothelial growth factor (VEGF) was
mostly expressed (in addition to glomeruli) in tubuli
showing a diffuse cytoplasmic or an apical staining pattern
(Figure 6e–g). Somewhat surprisingly VEGF expression in
NPHS1 kidneys was decreased by 30% (P-value NS) and 52%
(Po0.01) when compared with control groups 1 and 2,
respectively (Figure 6h). Both western blot analysis and the
PCR microarray of the kidney cortex samples showed equal
reduction in the VEGF expression (Figures 5c, 6i and j). The
overall profile of the angiogenic molecules in the microarray
showed neither up- nor downregulation of the VEGF-related
molecules (Figure 5c).
In the NPHS1 kidneys, heavy proteinuria and dyslipide-
mia lead to arteriolar obliteration already visible in kidneys
removed at infancy (Figure 1). The possible role of
thrombotic events in PTCs was evaluated by direct micro-
scopy (Herowitc staining) but it did not show thrombi in
PTC. Also, staining for a prothrombotic vonWillebrand
factor and the platelet marker CD61 did not indicate
thrombus formation in PTCs (Figure 7a–c). Interestingly,
the staining pattern of fibrin in PTCs of NPHS1 kidneys
showed great variation from sample to sample (Figure 7d and
e). Fibrin staining was not detected in samples of control
group 2 (Figure 7f).
DISCUSSION
We examined morphological and molecular changes of
PTCs in NPHS1 kidneys. In this disease, mutations in
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Figure 3 | Double stainings of CD31 with a-SMA, vimentin, and
CD34. (a and b) Possible transformation of PTC endothelial cells
to mesencymal cell was studied by double IF staining for CD31
and a-SMA. The analysis of 96 visual fields in NPHS1 kidneys,
however, did not reveal costaining of these two markers. (c and d)
Double staining for CD31 and vimentin showed strong and early
expression of vimentin both in PTC endothelium and in the
surrounding peritubular space. (e and f) The expression of CD31
and CD34 was mostly colocalized in endothelial cells. (g and h)
Small foci with stronger expression of CD34 were seen among the
cellular infiltrates. (Original magnification 400).
1102 Kidney International (2009) 75, 1099–1108
o r i g i n a l a r t i c l e A Kaukinen et al.: PTCs in kidneys with NPHS1
podocyte-specific nephrin affect only glomeruli, and the
interesting question is how the glomerular injury is
transmitted to tubulointerstitium leading to renal fibrosis.
Our results suggest that hypoperfusion and injury in
glomerular and PTCs may result in interstitial hypoxia and
fibrosis as well as tubular damage.
Chronic hypoxia is regarded as a major factor contributing
to the development of renal fibrosis.18 PTCs are essential for
supplying oxygen to the tubular system and their role has
recently been emphasized both in renal diseases and chronic
allograft nephropathy.14,22,23 In our study, increased amount
of HIF-1a was found in the tubulointerstitium of NPHS1
kidneys implicating low oxygen tension. The most probable
explanation for this was hypoperfusion in PTCs, caused by
the obliteration of the atherosclerotic arterioles, glomerular
capillaries, and PTCs, as observed in this work and our
previous studies.6,7 Mesangial expansion and glomerular
capillary obliteration develop early in NPHS1 kidneys
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Figure 4 | The expression of adhesion molecules and their ligands in peritubular space of NPHS1 kidneys. (a) The staining intensity
for ICAM-1 was 1.5 times (Po0.01) higher in NPHS1 kidneys as compared with control group 1, whereas its expression was equal to control
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reducing circulations in PTCs, which reside downstream to
glomeruli. Swelling and dilatation of the tubuli due to
massive proteinuria also favours hypoperfusion in PTCs.
Whether vascular thrombi in PTCs were an additional factor
in tubulointerstitial ischemia was evaluated by the immuno-
histochemical studies on the platelet marker CD61. Only a
few CD61-positive foci, however, were observed indicating a
minor role for the thrombus formation in PTCs.
Loss of PTCs was clearly associated with the development
of interstitial fibrosis (collagen I expression) and appearance
of myofibroblasts (a-SMA expression). Hypoxia is known to
induce transformation of interstitial fibroblasts into myofi-
broblast,24,25 which seems as a possible trigger also in NPHS1
kidneys. Transformation of endothelial cells into myofibro-
blasts has also been recently suggested,26,27 but double
staining for CD31 and a-SMA did not show such foci in
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Figure 5 | The analysis of real-time reverse transcription–PCR from NPHS1 kidney cortex. (a–c) The analysis was carried out for important
adhesion molecules, cytokines, and molecules related to thrombin activity and VEGF receptor molecules. The results are presented as fold of
mRNA changes in NPHS1 samples compared with control samples. The array was carried out in triplicate from each three NPHS1 patient samples.
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NPHS1 kidneys. Instead, we found an interesting association
of PTCs and another cytoskeleton protein vimentin. In
NPHS1 kidneys, vimentin was clearly an early marker for
peritubular and tubular lesions, and double staining for
CD31 and vimentin showed small foci with vimentin
expression and loss of PTCs. Early vimentin expression has
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recently been reported in some kidney disorders and renal
transplants,28–30 and the association of this with PTC loss
seems interesting.
Besides hypoxia, proteinuria is an important factor in the
development of renal fibrosis.31,32 Filtered macromolecules
may exert critical effects on tubular cells leading to
tubulointerstitial injury, epithelial–mesenchymal transforma-
tion, and production of proinflammatory and profibrotic
cytokines and chemokines.33 Our previous studies indicated
that tubular cells in the NPHS1 kidneys were quite resistant
to proteinuria and showed little epithelial–mesenchymal
transformation.5 In this work, the cortical expression of
mRNAs of several cytokines, such as interleukins and tumor
necrosis factor, was lower in NPHS1 kidneys as compared
with controls, and few inflammatory cells were found in the
well preserved peritubular areas. Moreover, the mesangial
expansion and periglomerular inflammation seemed to
precede tubulointerstitial damage in the NPHS1 kidneys.
These findings do not exclude the direct effects of proteinuria
on the tubulointerstitium but suggest that hypoperfusion is
an important factor for the development of interstitial
fibrosis. These data are in agreement with the recent findings
by Wong et al.,34 who found that reduction of parent
glomerular capillaries and hypoxic insults more strongly
influenced PTC flow and tubulointerstitial damage than
proteinuria alone in a model of subacute renal disease.
The PTC injury may result in endothelial activation with
enhancement of inflammation and thrombotic events.35,36
High plasma cholesterol and triglyceride levels may also
induce endothelial dysfunction in severely nephrotic NPHS1
patients.37 Adhesion molecules propagate the inflammatory
response and facilitate the adherence of leukocytes to the
microvascular endothelium.38 Our results on the expression
of adhesion molecules and their ligands were mixed.
Although strong expression of ICAM-1 was evident in the
PTCs of NPHS1 kidneys, the expression of P-selectin,
VCAM-1, and E-selectin was quite weak in the immuno-
staining. Also, the pattern of mRNA expression in the PCR
microarray did not show uniform activation of adhesion
molecules. ICAM-1 is the main endothelial ligand for b2-
integrin and it is involved in the transmigration of
lymphocytes and neutrophils expressing leukocyte function
antigen-1, which was also upregulated in NPHS1 kidneys.39
Elevated ICAM-1 levels have also been reported in other
nephrotic disorders but its role in these non-inflammatory
disorders remains open.40–42 Somewhat surprisingly, the
expression of VCAM-1, which binds to b1-integrins and, in
addition to leukocyte recruitment, is involved in athero-
sclerotic processes, was very low in NPHS1 kidneys.43
Angiogenesis is believed to be an important mechanism in
the maintenance of vascular integrity in the ischemic and
inflammatory renal disorders.44 Local production of angio-
genesis factors, proliferation of endothelial cells, and recruit-
ment of endothelial progenitor cells are involved in the repair
process. On the basis of this, it was surprising that the
expression of the major angiogenesis factor VEGF was low in
NPHS1 kidneys as studied by immunohistochemistry,
western blotting, and PCR microarray. Also, the PCR
microarray did not show upregulation of mRNAs of VEGF
receptors. Moreover, the expression level of b1-integrins, that
are believed to be involved in angiogenesis,45 was low in
immunostaining and PCR microarray. These data are in
contrast to some animal models46 but they are in agreement
with the recent results of Lindenmeyer et al.,47 who found
reduced VEGF expression in the tubulointerstitium of
human diabetic kidneys with interstitial vascular rarefaction.
The possible role of endothelial progenitor cells in vascular
repair was studied by double staining for the endothelial
progenitor cell markers CD34 and CD31 (mature endothelial
cells). The stainings, however, did not show vascular
structures with high CD34 and low CD31 expression. These
data indicate that the reparative capability of NPHS1 kidneys
is limited, which fits to the fast progression of fibrosis.
The NPHS1 kidneys, nephrectomized at an early stage
when renal function still is quite normal, serve as a unique
model for studies on the pathophysiology of nephrotic
kidney diseases. The problem is that it is not possible to
obtain normal age-matched kidney material (not showing
dysplasia or cellular damage caused by cytotoxic drugs).
Therefore, tissue samples from adult kidneys with normal
histology and function (control group 1) and biopsies from
children, aged 2–14 years, who suffered from proteinuric
disorders (mostly minimal change nephrotic syndrome)
(control group 2) was used as controls. So, caution is
warranted in the interpretation of the results dealing with the
expression levels of some molecular markers. Most of the
data on NPHS1 kidneys presented is, however, valid without
optimal controls. This is especially the case with the
histological findings and the expression of many markers
(abundant vs little expression).
In conclusion, hypoperfusion of PTCs and tubulointer-
stitial hypoxia were evident in NPHS1 kidneys. Vimentin
expression was an early marker for tubulointerstitail lesions
associated with the PTC loss. The inflammatory response of
PTCs was seen as an upregulation of ICAM-1 expression.
Endothelial–mesenchymal transformation was not observed
and, based on the analysis of angiogenesis factors and the
CD34 expression, vascular repair of PTCs was modest.
MATERIALS AND METHODS
Kidney tissue samples
The kidney samples came from 44 children with NPHS1 (age 3–44
months), nephrectomised at the Hospital for Children and
Adolescents, University of Helsinki, Finland in 1986–2006. The
genotypes of the NPHS1 patients were as follows: Fin-major
homozygotes 32 patients, Fin-major/Fin-minor compound hetero-
zygotes 5 patients, Fin-minor homozygotes 3 patients, and Fin-
major/missense mutation 4 patients. We did not find any association
with the genotype and the pathological findings. Routine formalin-
fixed and paraffin-embedded samples were prepared, and the rest of
the renal cortex was snap-frozen in liquid nitrogen and stored at
70 1C. All patients had severe nephrotic syndrome from the birth
and were treated with daily albumin infusions to supplement the
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continuous heavy protein losses. As a control group 1 we used 10
normal adult kidneys (age 47–58 years) removed for transplantation.
These kidneys had proved unsuitable for transplantation mainly
because of vascular abnormalities. Control group 2 consisted of
biopsies from 14 children (age 2–14 years). Ten of these patients
suffered from minimal change nephrotic syndrome (U-Prot values:
22, 63, 133, 984, 554, 53, 70, 5170, 803, and 3170 mg/l at the time of
biopsy), three patients suffered from focal segmental glomerulo-
sclerosis (U-Prot values: 132, 2310, and 3220 mg/l), and one patient
had mesangioproliferative glomerulonefritis (U-Prot value:
2510 mg/l).
Antibodies
Antibodies used for immunofluorescence stainings included mouse
monoclonal antibodies against CD34 (Dako Cytomation, Glostrup,
Denmark), fibrin (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), HIF-1a (BD Transduction Laboratories, San Jose, CA, USA),
human SMA (Dako Cytomation, Glostrup, Denmark), and
vimentin (Dako Cytomation). Antibodies for immunofluorescence
included also rabbit polyclonal antibody against platelet endothelial
cell adhesion molecule-1 (CD31) (Novus Biologicals Inc., Littleton,
CO, USA).
Antibodies for immunoperoxidase stainings included mouse
monoclonal antibodies against CD29 (Visionbiosystems novocastra,
Newcastle upon Tyne, UK), CD61 (Dako Cytomation), CD34 (Dako
Cytomation), collagen I (Acris Antibodies, Hiddenhausen, Ger-
many), endothelial leukocyte adhesion molecule (ELAM-1, E-
selectin, CD62E) (R&D Systems, Minneapolis, MN, USA), human
SMA (Dako Cytomation), intercellular adhesion molecule-1
(ICAM-1, CD54) (R&D Systems), leukocyte function antigen-1
(LFA-1, CD11a) (Dako Cytomation), platelet endothelial cell
adhesion molecule-1 (PECAM-1, CD31) (Dako Cytomation),
P-selectin glycoprotein ligand (PSGL-1, CD162) (Santa Cruz
Biotechnology Inc.), Sialyl-LewisX (sLEX, CD15s) (BD Pharmingen,
San Jose, CA, USA), vascular cell adhesion molecule-1 (VCAM-1,
CD106) (R&D Systems), very late antigen-4 (VLA-4, CD49d)
(Serotec, Oxford, UK). Antibodies for immunoperoxidase stainings
also included goat polyclonal antibody against P-selectin (Santa
Cruz Biotechnology Inc.).
Microscopy and immunohistochemistry
The histological lesions in NPHS1 kidneys were evaluated by light
microscopy from paraffin-embedded tissue sections stained with
periodic acid silver methenamin.
Immunoperoxidase stainings were performed in a traditional
way using sections of formalin-fixed, paraffin-embedded or snap-
frozen, acetone-fixed cryosections (5 mm) of kidney tissue samples.
In the immunoperoxidase staining of the cryosections, a peroxidase-
conjugated rabbit anti-mouse (Dako, Copenhagen, Denmark) and
peroxidase-conjugated goat anti-rabbit antibody (Zymed, San
Franciso, CA, USA) were used as second antibodies. The reaction
was revealed by 3-amino-9-ethyl carbazole solution containing
hydrogen peroxide; Mayer’s hemalum was used for counterstaining.
When staining formalin-fixed, paraffin-embedded sections, micro-
wave treatment in 10 mmol/l citric acid for 10 min was performed or
Dako Target Retrieval Solution (S1699) (Dako Cytomation) was
used to improve the antibody penetration. Amplification of the
primary antibody reaction was achieved by incubating the sections
with biotinylated secondary antibody (Vector Elite ABC Kit) (Vector
Laboratories Inc., Burlingame, CA, USA) or TSA Indirect, tyramide
signal amplification-kit (Perkin Elmer LAS Inc., NEL700). For the
immunofluorescence stainings the cryosections (5 mm) of kidney
samples were fixed with acetone or 3.5% paraformaldehyde,
depending on the antibody used. The stainings were performed in
a conventional way.5
Semiquatitative scoring system
Randomly selected visual fields from kidney interstitium sample
were analyzed at  400 magnification in the light microscope for
the following parameters: (1) Mean area fraction (%) of CD31-
positive PTCs per number of tubuli in each visual field. Images were
analyzed by NIH ImageJ 1.35p program (National Institutes of
Health, USA) by calculating the area fractions of immunostained
components. The proportion of black-to-white pixels in the image
was calculated as percentage. (2) Mean number of CD31-positive
PTCs per number of tubuli in each visual field. (3) The number of
adhesion molecules, their ligands, and HIF-1a-positive PTCs were
calculated and results are presented as positive foci per visual field.
Total RNA isolation and real-time reverse transcription–PCR
Total RNA from cortical tissues from control and NPHS1 patients
was isolated with TRIzol Reagent (Invitrogen Life Technologies,
Carlsbad, CA, USA) and further purified with Rneasy Mini Kit
(QIAGEN, GmbH, Germany) according to the manufacturer’s
protocols. cDNA synthesis was carried out with an RT2 PCR Array
First Strand Kit (C-02) (SuperArray Bioscience Corporation,
Frederick, MD, USA) by incubating 2 mg of isolated RNA at
þ 37 1C for 1 h. The synthesized cDNA was subjected to real-time
PCR (ABI PRISM 7000; Applied Biosystems, Foster City, CA, USA)
using RT2 Real-Time SYBR Green/ROX PCR Master Mix (PA-112)
(SuperArray Bioscience Corporation). The Human Endothelial Cell
Biology RT2 Profiler PCR Array (APHS-015A) (SuperArray
Bioscience Corporation) was used to profile the expression of 84
genes related to endothelial cell biology. The PCR was amplified for
40 cycles. Each PCR was subjected to melting curve analysis.
Threshold cycles for each primer were separately analyzed. The
following equation was used to normalize the expression level of a
gene of interest (GOI) to a housekeeping gene (HKG¼ b-
actin)¼ 2[Ct(GOI)–Ct(HKG)]¼ 2DCt. To determine the gene expres-
sion profile in NPHS1 cortical tissues, the normalized expression of
the GOI in the experimental sample (DCt expt) was divided by the
normalized expression of the same GOI in the control sample (DCt
control), where DDCt¼DCt exptDCt control. Representative data
are presented in terms of fold mRNA changes of NPHS1 samples
compared with control samples.
Western blotting
The kidney cortex was homogenized with Ultra-Turrax (Rose
Scientific Ltd, Alberta, Canada) in 0.08 M Tris-HCl pH 6.8 buffer
containing 2% SDS and 10% glycerol. Western blotting was
performed in a conventional way as previously described.5
Antibodies for western blotting included anti-actin goat polyclonal
antibody (Santa Cruz Biotechnology Inc.), anti-HIF-1a mouse
monoclonal antibody (BD Transduction Laboratories), anti-VEGF
mouse monoclonal antibody (Santa Cruz Biotechnology Inc.),
donkey anti-goat IgG-HRP conjugated antibody (Santa Cruz
Biotechnology Inc.), and goat anti-mouse IgG-HRP conjugated
antibody (Santa Cruz Biotechnology Inc.).
Statistics
Data are presented as mean±s.d. Two-tailed P-values o0.05
(Student’s t-test) were considered significant.
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